News
-
-
PRESS RELEASE
19.3% Weight Loss at Week 48: Phase Ⅲ Data of Olatorepatide, Hansoh's Dual‑Biased GLP‑1/GIP Agonist, Presented at EASD
Phase III data of Hansoh Pharma's Olatorepatide, a dual-biased GLP-1/GIP agonist, showing 19.3% weight loss efficacy at Week 48 presented at EASD. Study demonstrates significant weight loss benefits and metabolic improvements